SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q/A-1 {X} QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 1996 Commission File No. 0-19131 MEDIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 52-1555759 (State or other jurisdiction of (I. R. S. Employer incorporation or organization) Identification No.) 35 West Watkins Mill Road, Gaithersburg, MD 20878 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code (301)417-0770 Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ] As of June 30, 1996, 21,655,284 shares of Common Stock, par value $0.01 per share, were outstanding. PART II OTHER INFORMATION Item 1. Legal Proceedings - None Item 2. Changes in Securities - None Item 3. Defaults upon Senior Securities - None Item 4. Submission of Matters to a Vote of Security Holders - [Change in number of authorized shares] Item 5. Other Information - None Item 6. Exhibits and Reports on Form 8-K (a) Exhibits: 10.57 Plasma Supply Agreement dated effective as of February 8, 1996, by and between DCI Management Group, Inc. and MedImmune, Inc. 10.58 License and Research Support Agreement dated as of April 16, 1996, between The Rockefeller University and MedImmune, Inc. 27 Financial Data Schedule (b) Reports on Form 8-K: Report Date Event reported 4/18/96 MedImmune and Rockefeller University Establish Collaboration to Discover and Commercialize Products for Prevention and Treatment of Streptococcus Pneumoniae 4/25/96 MedImmune Reports Product Sales Increase 116% for Q1 1996 6/6/96 MedImmune Secured Broad Patent Coverage for Human B19 Parvovirus Vaccine 6/20/96 MedImmune Announces Proposed Private Offering of Convertible Debt MedImmune Reports Data on New Lyme Disease Vaccine Candidate at International Lyme Meeting - Antibodies to Newly Discovered Decorin Binding Protein Prevent Infection in Animals 6/20/96 MedImmune In-Licenses Key Human Papillomavirus Vaccine Intellectual Property from German Cancer Research Center SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. MEDIMMUNE, INC. (Registrant) Date: October 3, 1996 /s/David M. Mott President and Chief Operating Officer (Principal accounting and financial officer)